Incyte finalizes the acquisition of Escient Pharmaceuticals
Incyte yesterday announced that it has completed its acquisition of Escient Pharmaceuticals, a clinical-stage drug discovery and development company advancing novel small molecule therapeutics for systemic immune and neuro-immune disorders. “The acquisition of Escient and its first-in-class oral MRGPR antagonists bolsters our Inflammation and Autoimmunity portfolio and our commitment to creating innovative solutions that address […]
Progentos Therapeutics closes USD 65MLn in series A financing
Progentos Therapeutics, a biotech company addressing the critical unmet need to regenerate myelin and restore function for patients with Multiple Sclerosis (MS) and other demyelinating diseases, recently announced its launch and the closing of a $65 million series A round. This funding will enable Progentos to advance its MS program through human proof of concept […]
Ipsen and Skyhawk Therapeutics ink an exclusive collaboration
Ipsen and Skyhawk Therapeutics announced the signing of an exclusive worldwide collaboration to discover and develop novel small molecules that modulate RNA for rare neurological diseases. The agreement includes an option pursuant to which Ipsen would acquire exclusive license for the worldwide rights to develop successful development candidates (DC). Following successful DC nomination, Ipsen will […]
BioDura-Sundia and X-Chem partner for DEL services in China
US based BioDuro-Sundia, one of the industry-leading drug discovery, development and commercial service CRDMO backed by Advent International, and US headquartered X-Chem, a DEL technology pioneer in small molecule drug discovery, jointly announced the launch of DNA Encoded Compound Library (DEL) technology services in China to help more innovative pharmaceutical companies quickly discover small molecule […]
